Severe Hypoglycemia Increases Dementia Risk and Related Mortality: A Nationwide, Population-Based Cohort Study

2022 ◽  
Author(s):  
Eugene Han ◽  
Kyung-do Han ◽  
Byung-Wan Lee ◽  
Eun Seok Kang ◽  
Bong-Soo Cha ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Alzheimer Disease ◽  
Vascular Dementia ◽  
Severe Hypoglycemia ◽  
National Health Insurance System ◽  
Health Checkup ◽  
Risk Of Death ◽  
Dementia Risk ◽  
Overall Mortality

Abstract Context There are few studies focused on the relationship between hypoglycemia and new-onset dementia in patients with type 2 diabetes and no study regarding mortality of dementia after hypoglycemia. Objective We investigated the effect of severe hypoglycemia on dementia subtypes and its relation to overall mortality in patients with type 2 diabetes. Methods We evaluated incident dementia, including Alzheimer disease and vascular dementia, among health checkup participants aged 40 years or older in the National Health Insurance System in Korea from January 2009 to December 2015. Episodes of severe hypoglycemia were examined for 3 years before the date of the health checkup. Results Among 2 032 689 participants (1 172 271 men, 860 418 women), 14 443 (0.7%) experienced severe hypoglycemia, during a mean follow-up period of 6.9 ± 1.7 years. Individuals in the severe hypoglycemia group were more likely to be diagnosed with dementia compared to individuals without severe hypoglycemia (23.3% vs 7.3%; P < .001) and the overall incidence of Alzheimer disease was higher than vascular dementia. Dementia risk rose with increasing number of severe hypoglycemic episodes (1 episode [hazard ratio (HR) = 1.54; 95% CI, 1.48-1.60], 2 or more episodes [HR = 1.80; 95% CI, 1.66-1.94]). Overall mortality was higher in participants with dementia, but without severe hypoglycemia (HR = 2.03; 95% CI, 1.96-2.10) and severe hypoglycemia, but without dementia (HR = 4.24; 95% CI, 4.29-4.40), and risk of death was highest in those with both severe hypoglycemia and dementia (HR = 5.08; 95% CI, 4.83-5.35). Conclusion Severe hypoglycemia is associated with dementia, especially Alzheimer disease and mortality; together, they have an additive effect on overall mortality.

scholarly journals Severe hypoglycemia and the risk of end stage renal disease in type 2 diabetes

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Jae-Seung Yun ◽  
Yong-Moon Park ◽  
Kyungdo Han ◽  
Hyung-Wook Kim ◽  
Seon-Ah Cha ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Severe Hypoglycemia ◽  
National Health Insurance System ◽  
Increased Risk ◽  
Baseline Evaluation ◽  
Stage Renal Disease ◽  
End Stage

AbstractWe investigated the association between the incidence of severe hypoglycemia and the risk of end-stage renal disease (ESRD) in patients with type 2 diabetes. Baseline and follow-up data for 988,333 participants with type 2 diabetes were retrieved from the National Health Insurance System database. The number of severe hypoglycemia episodes experienced from 2007 to 2009 was determined. The primary outcome was the development of ESRD after the baseline evaluation. Participants were followed from the baseline until death or December 31, 2016, during this period 14,545 participants (1.5%) developed ESRD. In the crude model, compared with those who experienced no severe hypoglycemia, the hazard ratios (95% confidential intervals) for developing ESRD were 4.96 (4.57–5.39), 6.84 (5.62–8.32), and 9.51 (7.14–12.66) in participants who experienced one, two, and three or more episodes of severe hypoglycemia, respectively. Further adjustment for various confounding factors attenuated the association between severe hypoglycemia and ESRD; the significance of the association between severe hypoglycemia and ESRD was maintained. Having three or more severe hypoglycemia episodes was associated with a nearly two-fold increased risk of developing ESRD. Prior episodes of severe hypoglycemia were associated with an increased risk of ESRD among Korean adults with type 2 diabetes.

Prevalence of Impaired Awareness of Hypoglycemia and Severe Hypoglycemia among People with Type 2 Diabetes Treated with Insulin—The Dutch Diabetes Pearl Cohort

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 106-OR
Author(s):  
LIAN VAN MEIJEL ◽  
DE VEGT FEMMIE ◽  
CORNELIS TACK ◽  
EVERTINE J. ABBINK ◽  
FEMKE RUTTERS ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Severe Hypoglycemia ◽  
Impaired Awareness

834-P: Weight Change and Dementia Risk in Patients with New-Onset Type 2 Diabetes: A Nationwide Cohort Study

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 834-P
Author(s):  
HYUK-SANG KWON ◽  
SOON JIB YOO ◽  
MIN-KYUNG LEE ◽  
GA EUN NAM
Keyword(s):  
Type 2 Diabetes ◽  
Cohort Study ◽  
Weight Change ◽  
Onset Type ◽  
Dementia Risk ◽  
New Onset

scholarly journals Lifetime risk of cardiovascular-renal disease in type 2 diabetes: a population-based study in 473399 individuals

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
R Zhang ◽  
J Mamza ◽  
T Morris ◽  
G Godfrey ◽  
F Asselbergs ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Renal Disease ◽  
Population Based ◽  
Lifetime Risk ◽  
Disease Stage ◽  
Renal Diseases ◽  
Funding Source ◽  
Private Company ◽  
Risk Of Death

Abstract Background Lifetime risks of cardiovascular (CV) and renal diseases are high, particularly in type 2 diabetes (T2D), but rarely studied together, and relative disease contributions are unknown. Knowledge of lifetime risk of cardiovascular-renal disease (CVRD) will better reflect disease burden in T2D. Purpose To investigate the lifetime risks (LTRs) of composite and individual components of major adverse reno-cardiovascular events, MARCE in T2D patients. Method In a population-based cohort study using national electronic health records, we studied 473399 individuals aged 45–99 years with T2D in England 2007–2018. The LTR of composite and individual components of MARCE (including CV death and CVRD: heart failure, HF; chronic kidney disease stage 3 and above, CKD; myocardial infarction, MI; stroke or peripheral artery disease, PAD) were estimated. LTRs by baseline CVRD comorbidity status were compared with individuals free from CVRD at baseline, accounting for the competing risk of death. Results Among T2D patients aged ≥45 years, the LTR of MARCE was 80% for individuals free from CVRD at baseline. LTR of MARCE was 97%, 93%, 98%, 89% and 91% for individuals with specific CVRD comorbidities for HF, CKD, MI, stroke and PAD, respectively at baseline. Within the CVRD-free cohort, LTR of CKD was highest at 54%, followed by CV death (41%), HF (29%), stroke (20%), MI (19%) and PAD (9%). Compared to CVRD-free, HF, MI and CKD at baseline were associated with the highest LTR of MARCE and its component diseases (Table). Conclusion The lifetime risk of CV disease and CKD in T2D patients is estimated to be over 60% and 50% respectively (1–3). When considered together, the LTR of MARCE is 80% in CVRD-free T2D patients, while nearly all those with T2D and HF will develop MARCE over their lifetime. Of the individual components of MARCE, LTR of CKD and HF were the highest among CVRD-free T2D patients. Preventive measures in T2D patients should be a priority in clinical practice to mitigate the burden of these complications. Funding Acknowledgement Type of funding source: Private company. Main funding source(s): AstraZeneca

scholarly journals Benfluorex and Mortality: A Fresh Perspective

2013 ◽  
Vol 2013 ◽  
pp. 1-9 ◽  
Author(s):  
Nicholas C. Harvey ◽  
Andrew Judge
Keyword(s):  
Type 2 Diabetes ◽  
Evidence Base ◽  
Valvular Regurgitation ◽  
Media Attention ◽  
Risk Of Death ◽  
Trade Name ◽  
Fresh Perspective

Benfluorex, a drug related to fenfluramine, has been sold under the trade name “Mediator” by Servier Laboratories and was introduced to the French market in 1976, licenced for the treatment of type 2 diabetes and dyslipidemia. Although the evidence that benfluorex increases the risk of mild valvular regurgitant abnormalities is convincing, it is also apparent that no data exist from which to calculate the risk of death attributable to benfluorex use. Despite this, two studies have attempted to make such estimates, the results of which have been the focus of much media attention. In this review, we attempt to provide a further assessment of the evidence base, explore the limitations of the estimates of death that have been made, and calculate the population risk of mild valvular regurgitation and hospitalisation attributable to benfluorex use. We conclude that the previously published estimates of deaths attributed to the use of this agent are unsafe, based on unfounded assumptions, and are highly likely to be inaccurate.

scholarly journals Body Weight Variability and the Risk of Cardiovascular Outcomes and Mortality in Patients with Type 2 Diabetes: a Nationwide Cohort Study

2020 ◽  
Author(s):  
Ga Eun Nam ◽  
Wonsock Kim ◽  
Kyungdo Han ◽  
Chung-woo Lee ◽  
Yeongkeun Kwon ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Body Weight ◽  
Large Scale ◽  
Cox Proportional Hazards ◽  
Cardiovascular Outcomes ◽  
National Health Insurance System ◽  
All Cause Mortality ◽  
Quartile Group ◽  
Diabetes Patients

<b>Objective: </b>Obesity and type 2 diabetes are risk factors for cardiovascular diseases and mortality, and that commonly result in weight variabilities. We aimed to investigate the association between body weight variability and risk of major cardiovascular outcomes and mortality in individuals with type 2 diabetes using large-scale, nationwide cohort data on the Korean population. <div><p><b>Research Design and Methods: </b>We enrolled 624,237 individuals with type 2 diabetes who underwent health examinations provided by the Korean National Health Insurance System between 2009 and 2010, with ≥3 body weight measurements within 5 years since enrollment and followed up until the end of 2017. We assessed body weight variability using four indices, including variability independent of the mean (VIM). Multivariable-adjusted Cox proportional hazards regression analysis was performed.</p> <p><b>Results: </b>During the follow-up, 15,832, 25,038, and 44,716 cases of myocardial infarction (MI), stroke, and all-cause mortality, respectively, were recorded. Body weight variability was associated with increased risks of major cardiovascular outcomes after adjusting for confounding variables. Compared with the hazard ratios (HRs) of the lowest quartile group, the HRs (95% CIs) of the highest quartile group of VIM for body weight were 1.15 (1.10–1.20), 1.22 (1.18–1.26), and 1.58 (1.53–1.62) for MI, stroke, and all-cause mortality, respectively.</p> <p><b>Conclusions: </b>Body weight variability was associated with increased risks of MI, stroke, and all-cause mortality in type 2 diabetes patients and may be a predictor of cardiovascular outcomes in such patients. Appropriate interventions to maintain stable weight could positively influence health outcomes in type 2 diabetes patients.</p> </div> <br>

Sign in / Sign up

Export Citation Format

Share Document